The trial is taking place at:
A

Ascension | Ascension Texas Cardiovascular

Veeva-enabled site

PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR

Edwards Lifesciences logo

Edwards Lifesciences

Status

Enrolling

Conditions

Aortic Valve Stenosis
Aortic Stenosis, Calcific

Treatments

Device: SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA

Study type

Interventional

Funder types

Industry

Identifiers

NCT04889872
2021-01

Details and patient eligibility

About

This study objective is to establish the safety and effectiveness of the Edwards SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve systems in subjects with moderate, calcific aortic stenosis. Following completion of enrollment, subjects will be eligible for enrollment in the continued access phase of the trial.

Full description

This is a prospective, randomized, controlled, multicenter study. Subjects will be randomized to either transcatheter aortic valve replacement (TAVR) with the SAPIEN 3 / SAPIEN 3 Ultra /SAPIEN 3 Ultra RESILIA THV or Clinical Surveillance.

Enrollment

2,250 estimated patients

Sex

All

Ages

65+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

  • 65 years of age or older at time of randomization
  • Moderate aortic stenosis
  • Subject has symptoms or evidence of cardiac damage/dysfunction
  • The subject or subject's legal representative has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent.

Key Exclusion Criteria:

  • Native aortic annulus size unsuitable for the THV
  • Anatomical characteristics that would preclude safe transfemoral placement of the introducer sheath or safe passage of the delivery system
  • Aortic valve is unicuspid or non-calcified
  • Bicuspid aortic valve with an aneurysmal ascending aorta > 4.5 cm or severe raphe/leaflet calcification
  • Pre-existing mechanical or bioprosthetic aortic valve
  • Severe aortic regurgitation
  • Prior balloon aortic valvuloplasty to treat severe AS
  • LVEF < 20%
  • Left ventricular outflow tract calcification that would increase the risk of annular rupture or significant paravalvular leak post-TAVR
  • Cardiac imaging evidence of intracardiac mass, thrombus, or vegetation
  • Coronary or aortic valve anatomy that increases the risk of coronary artery obstruction post-TAVR

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

2,250 participants in 2 patient groups

TAVR
Experimental group
Description:
Transcatheter Aortic Valve Replacement (TAVR)
Treatment:
Device: SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA
CS
No Intervention group
Description:
Clinical Surveillance (CS)

Trial contacts and locations

81

Loading...

Central trial contact

Edwards THV Clinical Affairs

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems